HR Execs on the Move

Canadian Association of Gastroenterology

www.cag-acg.org

 
Canadian Association of Gastroenterology is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Blue Cross of Idaho

Since 1945, we`ve taken our role as an Idaho-based health insurance company to heart. While the health insurance marketplace has experienced lots of change in recent years, we haven`t. As a not-for-profit, we`re mission-driven to help connect Idahoans to quality healthcare that is affordable and build strong networks and services with our customers in mind. With an annual economic impact of $456 million (in 2016), we lead the state and industry in addressing the cost of healthcare and creating transformative customer experiences with information, tools and services. Ultimately, we aim to create a brighter future for all of us. All we need are customer-centric leaders like you.

ForSight Labs, LLC

ForSight Labs, LLC is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Menlo Park, CA. To find more information about ForSight Labs, LLC, please visit www.forsightlabs.com

Health Care Excel Inc

Health Care Excel Inc is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Instrumed International

Instrumed International, Inc. is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.